Metabolites of an orally active antimicrobial prodrug, 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime, identified by liquid chromatography/tandem mass spectrometry
✍ Scribed by Lian Zhou; Dhiren R. Thakker; Robert D. Voyksner; Mariappan Anbazhagan; David W. Boykin; James E. Hall; Richard R. Tidwell
- Book ID
- 102377584
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 419 KB
- Volume
- 39
- Category
- Article
- ISSN
- 1076-5174
- DOI
- 10.1002/jms.591
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
DB75 (2,5‐bis(4‐amidinophenyl)furan) is a promising antimicrobial agent against African trypanosomiasis and Pneumocystis carinii pneumonia. However, it suffers from poor oral activity in rodent models for both infections. In contrast, a novel prodrug of DB75, 2,5‐bis(4‐amidinophenyl)furan‐bis‐O‐methylamidoxime (DB289), has excellent oral activity. DB289 is currently undergoing clinical investigation as a candidate drug to treat primary stage African trypanosomiasis and Pneumocystis carinii pneumonia. In this study, metabolites of DB289 formed after incubation with freshly isolated rat hepatocytes were characterized using liquid chromatography/ion trap mass spectrometry. Administration of DB289 and octadeuterated DB289 in a 1 : 1 mixture greatly facilitated metabolite identification by providing isotope patterns with twin ions separated by 8 m/z units in the ratio 1 : 1, in the extracted ion chromatograms of molecular ions and in the product ion mass spectra of metabolites. Ten metabolites were identified. Series of O‐demethylations and N‐dehydroxylations led to the metabolic activation of DB289 to DB75 with the production of four intermediate phase I metabolites. Phase II glucuronidation and sulfation led to the formation of four glucuronide and one sulfate metabolites. Copyright © 2004 John Wiley & Sons, Ltd.